Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Profitable MorphoSys Proves Value of Technology Partnership Model

This article was originally published in The Pink Sheet Daily

Executive Summary

A milestone payment from long-time partner Novartis helped German antibody company MorphoSys report record revenues, supporting a 23% increase in R&D spend without the need to tap investors.

You may also be interested in...



MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs

MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.

Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.

MorphoSys Fills Out Pipeline With Xencor Deal

After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel